Cargando…

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives

The use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irrever...

Descripción completa

Detalles Bibliográficos
Autores principales: Robak, Ewa, Robak, Tadeusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145705/
https://www.ncbi.nlm.nih.gov/pubmed/35628931
http://dx.doi.org/10.3390/jcm11102807
_version_ 1784716381075275776
author Robak, Ewa
Robak, Tadeusz
author_facet Robak, Ewa
Robak, Tadeusz
author_sort Robak, Ewa
collection PubMed
description The use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irreversible inhibitors, covalent reversible inhibitors, and non-covalent reversible inhibitors. Ibrutinib is the first covalent, irreversible BTK inhibitor approved in 2013 as a breakthrough therapy for chronic lymphocytic leukemia patients. Subsequently, two other covalent, irreversible, second-generation BTKis, acalabrutinib and zanubrutinib, have been developed for lymphoid malignancies to reduce the ibrutinib-mediated adverse effects. More recently, irreversible and reversible BTKis have been under development for immune-mediated diseases, including autoimmune hemolytic anemia, immune thrombocytopenia, multiple sclerosis, pemphigus vulgaris, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s disease, and chronic spontaneous urticaria, among others. This review article summarizes the preclinical and clinical evidence supporting the role of BTKis in various autoimmune, allergic, and inflammatory conditions.
format Online
Article
Text
id pubmed-9145705
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91457052022-05-29 Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives Robak, Ewa Robak, Tadeusz J Clin Med Review The use of Bruton’s tyrosine kinase (BTK) inhibitors has changed the management of patients with B-cell lymphoid malignancies. BTK is an important molecule that interconnects B-cell antigen receptor (BCR) signaling. BTK inhibitors (BTKis) are classified into three categories, namely covalent irreversible inhibitors, covalent reversible inhibitors, and non-covalent reversible inhibitors. Ibrutinib is the first covalent, irreversible BTK inhibitor approved in 2013 as a breakthrough therapy for chronic lymphocytic leukemia patients. Subsequently, two other covalent, irreversible, second-generation BTKis, acalabrutinib and zanubrutinib, have been developed for lymphoid malignancies to reduce the ibrutinib-mediated adverse effects. More recently, irreversible and reversible BTKis have been under development for immune-mediated diseases, including autoimmune hemolytic anemia, immune thrombocytopenia, multiple sclerosis, pemphigus vulgaris, atopic dermatitis, rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s disease, and chronic spontaneous urticaria, among others. This review article summarizes the preclinical and clinical evidence supporting the role of BTKis in various autoimmune, allergic, and inflammatory conditions. MDPI 2022-05-16 /pmc/articles/PMC9145705/ /pubmed/35628931 http://dx.doi.org/10.3390/jcm11102807 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Robak, Ewa
Robak, Tadeusz
Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
title Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
title_full Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
title_fullStr Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
title_full_unstemmed Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
title_short Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
title_sort bruton’s kinase inhibitors for the treatment of immunological diseases: current status and perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145705/
https://www.ncbi.nlm.nih.gov/pubmed/35628931
http://dx.doi.org/10.3390/jcm11102807
work_keys_str_mv AT robakewa brutonskinaseinhibitorsforthetreatmentofimmunologicaldiseasescurrentstatusandperspectives
AT robaktadeusz brutonskinaseinhibitorsforthetreatmentofimmunologicaldiseasescurrentstatusandperspectives